Reprieve Cardiovascular

In the 4th quarter of 2020, Deerfield invested in Reprieve Cardiovascular, Inc. through its Series A Preferred tranched financing. Reprieve is developing an automated technology that employs an algorithm that infuses a diuretic and fluid to maximize diuresis in patients with Acute Decompensated Heart Failure. The financing will be used to further develop the technology and demonstrate clinical utility.